Eisai and Biogen’s Alzheimer’s drug price not expected to depress demand, analysts sayBy Publishing TeamJanuary 15, 2023 Jan 9 (Reuters) – The $26,500-a-year price for Eisai Co Ltd (4523.T) and Biogen Inc’s recently approved Alzheimer’s disease drug…
